Improvement of Metabolic Health After Thylakoid Supplementation

Overview

Objective: The purpose of this study was to investigate the possible effects of green-plant thylakoid supplementation to a restricted diet intervention study in overweight to obese men. Methods: Overweight-obese men (BMI 25 – 35) were treated to a 30 E% restricted diet for one month, followed by one month of stabilization. Then they were divided in two treatment arms of one month each; one thylakoid-enriched diet (n=10) and one control diet (n=10). Body measurements and blood samples were taken throughout the study.

Full Title of Study: “Metabolic Risk Markers and Body Weight Are Decreased by Green-plant Supplementation in a Pilot Study With Overweight-to-obese Middle-aged Men.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Participant)
  • Study Primary Completion Date: May 2010

Detailed Description

Twenty healthy, non-vegetarian, non-smoking Caucasian men were included in the study. Inclusion criteria: men aged 40 to 70 years with a BMI of 25 to 35. Exclusion criteria: Metabolic disturbances, bariatric surgery, recent diet, food allergies or treatment with antibiotics. The study protocol was approved by the Ethical Committee of Lund University, Sweden (#2006/361). The trial consisted of three periods: 1) diet-restriction period (one month) 2) stabilizing period (one month) 3) diet-restriction period with supplementation of thylakoids or placebo (one month). The two weight-losing periods included strict diet recommendation with -30 energy % (E%), and macronutrient composition: 55-65 E% carbohydrates, 10-15 E% protein and 25-35 E% fat. Sixty minutes of low intensive exercise per day was also required. During the stabilizing month participants were instructed to eat a healthy diet to be able to keep their achieved weight-loss. Day 0, 28, 56 and 84 the participants arrived after 12-hour fasting for blood sampling and anthropometric measurements. The blood samples were analyzed for plasma-glucose, insulin, HbA1c, inflammation markers, cholecystokinin, ghrelin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triacylglycerol.

Interventions

  • Dietary Supplement: Thylakoids
  • Other: Control

Arms, Groups and Cohorts

  • Placebo Comparator: Control group
    • Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
  • Active Comparator: Thylakoid group
    • Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.

Clinical Trial Outcome Measures

Primary Measures

  • Body weight
    • Time Frame: 3 months

Secondary Measures

  • Waist circumference
    • Time Frame: 3 months
  • Blood lipids
    • Time Frame: 3 months
    • Total cholesterol, LDL, HDL and TAG are measured fasting every fourth week.
  • P-glucose and p-insulin
    • Time Frame: 3 months
    • P-glucose, p-insulin and HbA1c are measured fasting every fourth week.
  • Inflammatory markers
    • Time Frame: 3 months
    • CRP and TNF alpha are measured fasting every fourth week.
  • Appetite regulating hormones
    • Time Frame: 3 months
    • Ghrelin and leptin are measured fasting every fourth week.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy, overweight, non-vegetarian, non-smoking Exclusion Criteria:

  • Medication for metabolic disturbances, previous bariatric surgery, diabetes, had been on diet or treated with antibiotics during last 3 months, food-allergies

Gender Eligibility: Male

Minimum Age: 40 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Region Skane
  • Collaborator
    • Lund University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Eva-Lena Stenblom, M.D. – Region Skane
  • Overall Official(s)
    • Eva-Lena Stenblom, M.D., Principal Investigator, Lund University, Region Skane

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.